Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet. The Ajax acquisition was a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister acknowledging more work is needed to "rebuild confidence" in the transportation. Testing of the ...

LONDON, April 28 (Reuters) - Britain's defence readiness minister Luke Pollard said he had agreed to restart the army's acceptance of Ajax armoured vehicles from General Dynamics with ‌strict controls ...

The Ministry of Defence is planning a “phased approach” to relaunching the beleaguered Ajax armoured vehicle programme after the project was once again halted due to noise and vibration concerns. In ...

Of Lilly’s six M&A deals so far in 2026, half have been oncology focused. Credit: Jennie Book/Shutterstock.com. Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire ...

Eli Lilly LLY0.48%increase; up pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3B in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

April 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up ‌to $2.3 billion in cash, as the U.S. drugmaker looks to ...